HUDCO raises Rs 750 crore via NCDs at 6.52% coupon, to mature in 3 years
As per the regulatory filing on June 6, the Bond Allotment Committee approved a base issue size of Rs 500 crore with a green shoe option of Rs 250 crore, aggregating the total issue to Rs 750 crore. The NCDs have a tenure of three years, with annual interest payments scheduled on June 6 each year till maturity in 2028.
The coupon rate offered on these NCDs is 6.52%, and the bonds will be listed on BSE. Notably, these are unsecured instruments and do not carry any special rights or privileges. There has been no delay or default in interest or principal payment as per the company's disclosure.
This move strengthens HUDCO's financial position as it continues to finance infrastructure and housing projects aligned with its mission for a developed India.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Investments in debt instruments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
Anthem Biosciences IPO GMP live: Latest GMP suggests a strong listing on 21st July — should you hold or exit?
By Aditya Bhagchandani Published on July 19, 2025, 13:16 IST Anthem Biosciences, which closed its IPO bidding on July 16, is set to make its stock market debut on Monday, July 21, 2025. According to market observers, the IPO is likely to list strongly, with grey market premium (GMP) suggesting gains of over 23%. The IPO was open for subscription from July 14 to July 16, and share allotment was finalized on Thursday, July 17. The shares will be listed on both BSE and NSE. Key IPO details: IPO price band: ₹570 per share Retail minimum lot size: 26 shares (₹14,040) sNII minimum lot: 364 shares (₹2,07,480) bNII minimum lot: 1,768 shares (₹10,07,760) Employee reservation: Up to 1,58,654 shares at a ₹50 discount Book-running lead manager: JM Financial Registrar: KFin Technologies GMP indicates a strong debut According to , the Anthem Biosciences IPO GMP was ₹132 as of 9:56 AM on July 19, implying an estimated listing price of ₹702 per share — a potential gain of about 23.16% over the issue price. A day earlier on July 18, the GMP peaked at ₹144, indicating an estimated listing price of ₹714, or around 25.26% gains. How to check your IPO allotment? You can check the allotment status through the following platforms: On KFin Technologies website: Visit KFin Technologies' IPO allotment page. Select 'Anthem Biosciences Limited' from the company dropdown. Enter either your PAN or Application Number. View your allotment status. On NSE: Go to: NSE IPO Allotment page Select 'Equity & SME IPO bid details'. Enter your PAN and Application Number. Submit to check your status. On BSE: Visit BSE IPO Allotment page. Select 'Equity' as issue type and 'Anthem Biosciences IPO' from the list. Enter your Application Number or PAN. Click search to view your allotment status. Hold or exit? With a GMP suggesting a premium of over 23%, many investors expect a positive debut for Anthem Biosciences. However, GMP is not an assured indicator of listing day performance, and investors are advised to assess fundamentals and risk appetite before deciding whether to hold or book profits at listing. Disclaimer: The information above is based on publicly available sources and grey market data, which is unofficial and speculative. Investors should make informed decisions after consulting with financial advisors. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
a day ago
- Business Upturn
Brigade Hotel Ventures IPO: Key Details, Price Band, and Allotment
By Aditya Bhagchandani Published on July 19, 2025, 13:24 IST Brigade Hotel Ventures Limited, a subsidiary of Brigade Enterprises, is launching its IPO on July 24, 2025, which will close on July 28, 2025. The company has filed its Draft Red Herring Prospectus (DRHP) dated October 30, 2024. According to the DRHP and other filings: Issue Size: Approx. ₹759.6 crore, entirely a fresh issue . Face Value: ₹10 per equity share. Price Band: Not yet disclosed (to be finalized before opening). Retail Quota: Not more than 10%. QIB Quota: Not more than 75%. NII Quota: Not more than 15%. Listing: Shares will be listed on BSE & NSE , with trading expected to begin on July 31, 2025 . Book Running Lead Managers: JM Financial and ICICI Securities. Registrar: KFin Technologies. Financial Highlights: FY24 Revenue: ₹468.3 crore (up 16.6% YoY). FY24 Profit: ₹23.7 crore (down ~24% YoY). The company operates nine hotels (1,604 keys) under brands like Marriott, Accor, and IHG. Proceeds will primarily repay debt, purchase land from Brigade Enterprises, and support expansion plans. Notable Points: No offer-for-sale (OFS) component — all proceeds go to the company. A pre-IPO placement worth ₹126 crore was already completed on July 3, reducing the fresh issue from ₹900 crore to ₹759.6 crore. Debt repayment allocation: ₹468.1 crore. Land acquisition: ₹107.5 crore. The IPO aims to strengthen the company's balance sheet, expand operations, and support inorganic growth. Investors should watch out for the final price band and lot size, which are expected to be announced shortly. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Insider
a day ago
- Business Insider
AMD Stock Slips on Threadripper Pro Pricing
Advanced Micro Devices (AMD) stock was down on Friday after the semiconductor company revealed the price of its Threadripper Pro 9000 WX-Series CPUs. The Zen 5-based processors will start at $1,649 and will top out at $11,699 when they are released on July 23. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Investors might be sticker-shocked by the price of these new AMD processors, but it's worth noting these aren't for the average computer user. Instead, the Threadripper Pro line is designed with professionals in mind. The large number of cores allows them to be used in powerful applications, such as rendering and artificial intelligence (AI). AMD is also expected to release Threadripper processors that are more reasonably priced. These will lack the Pro designation, but will still offer plenty of power to computer builders. However, the company has yet to reveal how much these CPUs will set consumers back. AMD Stock Movement & Analyst Updates AMD stock was down 1.57% in pre-market trading on Friday, but remained up 30.81% year to date and 5.83% over the past 12 months. AMD stock has also received several analyst updates this week, as traders prepare for the release of the company's earnings report in early August and celebrate the end of an AI chip export ban on China. That coverage includes new ratings and price targets from top analysts. Bank of America Securities' Vivek Arya reiterated a Buy rating and increased his price target to $175 from $130. Mizuho Securities' Vijay Rakesh upgraded the stock to Buy and raised his price target to $175 from $152. Wells Fargo's Aaron Rakers maintained a Buy rating and boosted his price target to $185 from $120. Bernstein's Stacy Rasgon initiated coverage with a Hold rating and a $95 price target. Piper Sandler's Harsh Kumar kept a Buy rating and a $140 price target. Is AMD Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for AMD is Moderate Buy, based on 25 Buy and 10 Hold ratings over the past three months. With that comes an average AMD stock price target of $141.87, representing a potential 9.88% downside for the shares.
